Ignite Creation Date:
2024-05-06 @ 3:13 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04562870
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2020-09-09
Brief Title:
A Study to Evaluate Single Agent Selinexor Versus Physicians Choice in Participants with Previously Treated Myelofibrosis
Sponsor:
Karyopharm Therapeutics Inc
Organization:
Karyopharm Therapeutics Inc
Study Overview
Official Title:
A Phase 2 Randomized Open-Label Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physicians Choice in Patients with Previously Treated Myelofibrosis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 multicenter two-arm open-label study to evaluate the safety and efficacy of selinexor versus treatment per physicians choice PC in participants with myelofibrosis MF who had at least 6 months of treatment with a Janus kinase JAK12 inhibitor Study participants will be randomized in a 11 ratio to either receive selinexor or physicians choice of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-003809-60 | EUDRACT_NUMBER | None | None |